MyHealth Limited, a UK Health buisness, have launched a new biological therapy that treats asthma patients at home. MyAsthma Biologic was commissioned as part of the NHS AAC Rapid Uptake Products programme, which aims to improve access to biological therapies deliver efficient and specialist patient care.
MyAsthma Biologic
An extension to my Myhealth’s existing myAsthma product, the MyAsthma Biologic aims to support patients with severe asthma across the United Kingdom. The digital therapeutic supports patients in managing their asthma, and their clinical teams in managing and monitoring them remotely. The NHS is facing unprecedented pressures this winter, and it is anticipated that patients with respiratory disease may occupy up to half of all hospital beds.
Professor James Dodd, clinical lead of North Bristol’s complex airways service adds:
“With the growing number of highly effective monoclonal antibody therapies, and the growing demand on our services, we believe that digital therapeutics like MyAsthma Biologic will be increasingly important. Digital innovation has the potential to complement our dedicated multi-disciplinary team to increase capacity and enhance the support patients need to keep them well.”
Working in partnership with the University Hospital of Southampton (UHS) and the Accelerated Access Collaborative (AAC), the digital therapeutic technology offers flexible and hybrid treatment to Asthma sufferers who are at high risk of hospitalization. The product will also facilitate the collection of clinical data by automatically uploading information to the national asthma registry. Sites currently inputting data in the severe asthma registry and prescribing asthma biologics will have access to MyAsthma Biologic.
Simon Bourne, Company President at my mhealth comments:
“As a respiratory focused digital therapeutics company, we are honoured to have been chosen to roll out our product nationally to better support patients on biologics, who are living with Severe Asthma. We have already seen the huge potential of digital therapeutics to improve patients’ symptoms and quality of life and deliver efficiencies across primary and community health care services and look forward to working with the specialist severe asthma centres across the UK.’’
About my mhealth
My mhealth’s digital therapeutics have been prescribed to over 90,000 patients with chronic conditions, resulting in reduced morbidity and hospital admissions. It serves patients across a range of long-term conditions, including COPD, asthma, diabetes, and cardiovascular diseases. Real world and clinical trial evidence demonstrates the efficacy of digital interventions on the my mhealth platform.
